Galunisertib enhances chimeric antigen receptor-modified T cell function
Chimeric antigen receptor (CAR) T cell therapy still faces the challenge of immunosuppression when treating solid tumors. TGF-β is one of the critical factors in the tumor microenvironment to help tumors escape surveillance by the immune system. Here we tried using the combination of a small molecul...
Main Authors: | Zhixiong Wang, Qian Liu, Na Risu, Jiayu Fu, Yan Zou, Jiaxing Tang, Long Li, Hui Liu, Guomin Zhou, Xuekai Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2020-06-01
|
Series: | European Journal of Histochemistry |
Subjects: | |
Online Access: | https://www.ejh.it/index.php/ejh/article/view/3122 |
Similar Items
-
Chimeric Antigen Receptor T Cell and Chimeric Antigen Receptor NK Cell Therapy in Pediatric and Adult High-Grade Glioma—Recent Advances
by: Adrian Kowalczyk, et al.
Published: (2024-01-01) -
Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies
by: Joslyn L. Mangal, et al.
Published: (2021-03-01) -
Progress of Chimeric Antigen Receptor Gene Modified-T Cell Immunotherapy for Thoracic Malignancies
by: CHEN Fukun, et al.
Published: (2023-10-01) -
Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer
by: Amy J. Petty, et al.
Published: (2020-03-01) -
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future
by: Samer A. Srour, et al.
Published: (2023-01-01)